Treatment Protocol for Incidental Prostate Cancer After HoLEP

Amy E. Krambeck, MD, chief of the Division of Endourology and Stone Disease at Northwestern Medicine, has diagnosed prostate cancer in nearly 13% of her patients who underwent holmium laser enucleation of the prostate (HoLEP) for benign prostatic hyperplasia in the past year. In a recent episode of the Better Edge podcast, she and Ashley E. Ross, MD, PhD, associate professor of Urology at Northwestern Medicine, discuss the active surveillance protocol they developed for managing incidental prostate cancer after HoLEP. breakthroughsf...